Close

EBNA3C

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EBNA3C is encoded by Epstein-Barr virus (EBV), which is one of the latent proteins. As a potent transcriptional coregulator that interacts with numerous cellular proteins, EBNA3C is essentially involved in regulating multiple important cellular pathways, including cell cycle and apoptosism. Therefore, EBNA3C is playing a critical role in EBV-induced growth transformation of primary B lymphocytes. EBNA3C is related to Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), and AIDS-associated lymphomas.

Associated Disease
  • Burkitt's lymphoma (BL)
  • Nasopharyngeal carcinoma (NPC)
  • AIDS-associated lymphomas.
  • Others
  • CAR Vector Products

  • TCR Vector Products

  • TCR Cell Products

  • CAR Viral Particles

  • TCR Viral Particles

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-MZ043 Anti-EBNA3C (EBNA Clone 315) h(41BB-CD3ζ) CAR, pCDCAR1 Virus EBNA Clone 315 Human scFv-41BB-CD3ζ Retroviral NK cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.